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fact that a new therapy containing an artemisinin-based 
drug would have been the sixth ACT on the market, has 
led to a move away from the development of ferroquine–
artesunate com binations. However, ferroquine itself has 
tremendous potential. By contrast with many malaria 
medicines, it has never been deployed as monotherapy, 
and has no pre-existing cross-resistances against other 
medicines.10,11 However, its activity against the parasites 
that are resistant to second-generation chloroquines 
such as amodiaquine and piperaquine will need to be 
continually monitored and conﬁ rmed. Ferroquine could 
therefore make an ideal partner for one of the newer 
molecules in the global malaria portfolio.12 At least four 
such new molecules with long half-lives are being tested 
in patients, which could provide mutual protection 
against resistance in a combination therapy. The choice 
of right partner and the best regimen are diﬃ  cult 
decisions to make, but the good news from the patients’ 
perspective is that the chloroquine family has yielded a 
third-generation molecule, expanding our options in the 
ﬁ ght against malaria. 
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Typing of Neisseria meningitidis by whole-genome analysis 
Neisseria meningitidis is a Gram-negative diplococcal 
bacterium that can harmlessly inhabit the human 
nasopharynx. For reasons not completely understood, 
meningococci can invade the mucous membrane and 
gain access to the bloodstream, leading to meningitis, 
severe sepsis, or localised infections involving the joints or 
heart. Invasive meningococcal disease (IMD) can progress 
rapidly in previously healthy adolescents or young adults, 
is associated with mortality of about 10%, and occurs 
worldwide, although with geographical and topological 
variations in prevalence and the serogroups and clonal 
types of strains involved.1 The reasons for these variations 
remain unclear. Nevertheless, six serogroups (A, B, C, W, 
X, and Y) of 12 and a handful of clones that are deﬁ ned as 
hypervirulent lineages cause most of the disease burden.2 
Whole-genome sequencing (WGS) has been explored 
as a method for bacterial characterisation. With this 
technology becoming increasingly available and 
aﬀ ordable, Dorothea Hill and colleagues,3 in The Lancet 
Infectious Diseases, expanded on the idea of gene-by-
gene comparative analysis, originally introduced for 
multilocus sequencing typing (MLST),4 to create a new 
platform called the Bacterial Isolate Genomic Sequence 
database that can handle WGS data.5–7 De-novo 
assembled draft genomes or contiguous sequences 
from WGS analysis can be uploaded for gene-by-gene 
interrogation of known alleles at multiple loci stored 
in the system. To investigate the usefulness of this new 
platform to routine surveillance, Hill and colleagues 
analysed WGS data for all Neisseria meningitidis IMD 
isolates (n=899) submitted to the Public Health 
England Meningococcal Reference Unit for England 
and Wales in the epidemiological years 2010–11 and 
2011–12. Data on serogroups of cultured isolates and 
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their de-novo draft genomes, assembled (from WGS 
data) by previously validated procedures, were analysed 
together. This platform for handling WGS data was 
ﬂ exible enough to allow the investigators to set the 
level and the type of analysis they required on the basis 
of clinical or research questions. For example, typing 
could be done with the conventional seven genes used 
in MLST, 49 ribosomal protein gene loci, or 1605 core-
genome MLST. The inclusion of genes associated with 
antibiotic susceptibility or vaccine antigen targets 
into the analysis can be used to predict antibiotic 
susceptibility and vaccine coverage. 
Hill and colleagues identiﬁ ed at least 20 meningo-
coccal lineages showing substantial strain diversity 
and extensive recombination. Hyperinvasive clonal 
complexes 41/44 (lineage 3), 269 (lineage 2), and 23 
(lineage 23) accounted for 528 (59%) of IMD isolates. 
Coupling of the WGS analysis with patients’ demographic 
data enabled investigation of the relation between 
meningococcal lineages and disease in diﬀ erent age 
groups. Hill and colleagues found that speciﬁ c lineages 
were strongly associated with IMD in particular age 
groups and that diversity was substantial in the youngest 
and oldest individuals. The allelic analysis of WGS 
data also showed high diversity of the meningococcal 
group B vaccine antigens among clinical isolates, 
which might help to predict strain coverage of the 
Bexsero group B vaccine (GlaxoSmithKline, Brentford, 
Middlesex, UK), which is now available in the UK. The 
high resolution of ribosomal and core-genome MLST 
deﬁ ned several sublineages, for instance in lineage 11 
(clonal complex 11) and lineage 2 (clonal complex 269). 
Sublineage 11.1 corresponds to the classic ET-37 clonal 
complex8 and sublineage 11.2 corresponds to the ET-15 
variant of the parent ET-37 clonal complex.9 
Although use of meningococcal serogroup C 
conjugate vaccine has reduced the disease burden to 
a minimum, low levels of activity remain in the UK. 
In Canada, reduction in meningococcal serogroup C 
levels has been associated with a concomitant shift 
in strain from the predominant ET-15 (lineage 11.2) 
to ET-37 (lineage 11.1), as conﬁ rmed with antigenic 
and genetic analyses.10 With use of WGS data, lineage 
2 has been resolved into sublineages 2.1 and 2.2, for 
which the corresponding founding sequence types are 
269 and 275, respectively. In the UK, prevalence of these 
two sublineages has ﬂ uctuated over time,11 whereas 
in  Canada strains of lineage 2.1 have been persistently 
common and have caused localised outbreaks since ﬁ rst 
emerging in Quebec in 2003.12,13
The WGS typing platform described by Hill and 
colleagues3 is a suitable method for studying the 
epidemiology of IMD in England and Wales. The 
robustness and user-friendly and portable features 
might prove to be useful for worldwide analysis of 
IMD, including comparison of strain characteristics of 
similar or identical lineages in diﬀ erent regions where 
epidemiology diﬀ ers. 
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